OBJECTIVE: To assess the efficacy and tolerability of bortezomib with dexamethasone for @entity1 with renal light chain ( @entity1582 ) @entity2783 . METHODS: Twelve newly diagnosed @entity1 with @entity12042 were treated with a combination of bortezomib (1.3mg/m(2)/d iv, d1, 4, 8, 11) and dexamethasone (20mg/d iv drip, d1-4). RESULTS: Median follow-up time was 22.5months (range, 2.1-53.6). Ten @entity1 were evaluable. Five out of 10 (50%) @entity1 achieved @entity1503 ( @entity1503 ), and totally 8/10 (80%) achieved hematologic responses (HR). Median time to hematologic response was 1month. All @entity1 who received HR had no hematologic progression during follow-up period. Five @entity1 (50%) had kidney responses and the other 5 @entity1 (50%) were stable. Median time to kidney response was 3months. No @entity1 presented renal progression during follow-up. One @entity1 achieved PR after 4 cycles of VD and then received autologous peripheral blood stem cell transplantation. Two out of 10 evaluable @entity1 without hematologic response had died with median overall survival of 8.2months. Eight of them who had HR were alive with median follow-up time of 28.5months. Infection (6/12) and fatigue (5/12) were the most frequent side effects. Three @entity1 developed @entity4091 and had to discontinue therapy. CONCLUSIONS: VD produces rapid, deep and durable hematological responses and renal responses in the majority of @entity1 with newly diagnosed @entity8 . It is well tolerated. This treatment may be a good option as first-line treatment for @entity12042 @entity1 .

Successful treatment of renal light chain ( @entity1582 ) XXXX with bortezomib and dexamethasone (VD).

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal AL'] @entity12042 :: ('MESH:C538249', 'Disease') :: ['renal AL amyloidosis'] @entity2783 :: ('MESH:D000686', 'Disease') :: ['amyloidosis'] @entity4091 :: ('MESH:D006562', 'Disease') :: ['herpes zoster'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['AL'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['complete hematologic responses', 'CHR']
@entity2783 :: (MESH:D000686,Disease) :: ['amyloidosis']
